📰 Clinical Development Program News
Page 6 - Clinical Development Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Development Program. Real-time updates on events, politics, business and more.
May 1, 2023
Almirall S.A. today announced results from a new secondary analysis from the Phase 3 clinical development program which showed patients receiving lebrikizumab who were assessed at 16 weeks... | May 1, 2023
April 27, 2023
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72...
April 26, 2023
/PRNewswire/ -- Two Chairs, a modern behavioral healthcare company, today announced that it has joined the Aetna®, a CVS Health® company, network as a national...
April 25, 2023
‒ Post-hoc analyses from four Phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in wet age-related macular degeneration and diabetic macular edema ... | April 25, 2023
April 25, 2023
Post-hoc analyses from four Phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in wet age-related macular degeneration (AMD) and diabetic macular edema (DME) - More
April 13, 2023
‒ Vabysmo data suggest rapid and robust drying of retinal fluid in patients with wet age-related macular degeneration and diabetic macular edema – ‒ Real-wo ...
April 13, 2023
‒ Vabysmo data suggest rapid and robust drying of retinal fluid in patients with wet age-related macular degeneration and diabetic macular edema –‒ Real-world studies of Vabysmo demonstrate ability to extend treatment intervals in the first four months while maintaining visual acuity –‒ Clinical data on an investiga...
February 28, 2023
Achieved revenues in fourth quarter 2022 of $357 million and full year 2022 of $2.0 billion Appointed John C. Jacobs as President and Chief Executive Officer...
February 13, 2023
HAYWARD, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic
February 2, 2023
PARIS, France, February 2nd, 2023, 08:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative